



Arpeggio Bio

One-Sentence Summary of What You Do: Arpeggio Bio uses machine learning and RNA to make drugs against previously undruggable targets in cancer and inflammation diseases.

9 ~~cl~~ \ ~~A~~ ~~kl~~ ~~ant~~ ~~af~~ 2University of Colorado Boulder

@Yn] 'qgm^tje] \ Y [ge hYf q'q] | 7 Yes

>nf \ af _' >af Yf [af _2Grant Funding, WU ~~U~~ ~~H~~ ~~A~~ ~~H~~ ~~Y~~ ~~M~~ ~~R~~ ~~Z~~ ~~K~~ ~~Z~~ ~~M~~ ~~S~~ ~~N~~ ~~Z~~ ~~H~~

~~B~~~~B~~~~K~~~~N~~~~B~~~~K~~~~V~~~~Y~~~~B~~~~N~~~~U~~~~Z~~ ~~U~~~~V~~~~U~~~~V~~~~Y~~~~V~~~~B~~~~Y~~~~V~~~~W~~
~~B~~~~Y~~~~B~~~~W~~~~Y~~~~B~~~~B~~~~N~~~~U~~~~B~~
~~Y~~~~M~~~~R~~~~B~~~~U~~~~K~~~~N~~~~B~~~~K~~~~B~~~~N~~~~B~~~~M~~~~S~~~~B~~
~~D~~~~V~~~~S~~~~N~~~~B~~~~W~~~~B~~~~R~~~~Y~~~~U~~~~S~~~~N~~~~K~~~~Y~~~~B~~~~W~~~~Z~~
~~Z~~~~U~~~~K~~~~B~~~~K~~~~N~~~~B~~~~U~~~~N~~~~U~~~~W~~~~U~~

O` Yl 'ak'o Yk'qgnj _g%g% Yjc] I'kljYI] _q7 In 2020, there are more than one-hundred clinical trials involving drugs that directly alter gene expression; a 50% increase from 2019. In addition, Arpeggio is currently partnered with over 30 different Pharmaceutical companies helping them understand the impact their compounds have on gene expression. With both the increase in clinical candidates as well as market adoption of the Arpeggio platform, we feel there is a strong market and clinical need to create drugs that directly activate or inhibit gene expression. Arpeggio differentiates itself by our unique ability to isolate nascent RNA. Isolating nascent RNA allows our technology to profile gene expression changes on the order of minutes after drug exposure. This boost in sensitivity illuminates the direct mechanisms of a drug. Our machine learning algorithms trained on nascent RNA data can nominate new drug discovery targets at higher rates of accuracy. Currently, we've accessed the



DESTINATION STARTUP

business, we will also generate novel therapeutics to diseases with high unmet need. With our own drug assets, we will generate revenue through patent sub-licensing, royalty arrangements, and drug success milestone payments through co-development partnerships with larger pharmaceutical companies.

@go 'o atl` & k` go [Yk] 'Z] f] Pl` qgnj [ge hYf q'gj 'l] [` f gaj_q7 Arpeggio will be starting a series A fundraise in Q2 of 2021. With this in mind, we feel this event would be a great way to present our company to angel and venture capital. As a Boulder-based biotechnology startup, we want to specifically partner with funds in the Front Range area to continue to grow Colorado biotechnology entrepreneurship. We will be raising \$20M to develop our three current drug programs and perform IND-enabling studies. In addition, we are always on the look out for strategic partners as well

